Purpose: To study the spatial variances in ligand expression and angiogenic effect in response to the inflammatory response induced by basic fibroblast growth factor (b-FGF).
T he cornea is devoid of both blood and lymphatic vessels.
However, many pathological conditions of the cornea are associated with the ingrowth of new vessels from the preexisting vasculature of the limbus with resultant adverse consequences. 1, 2 Several key angiogenic factors, including fibroblast growth factor (FGF), 3 vascular endothelial growth factor (VEGF), [4] [5] [6] platelet-derived growth factor (PDGF), 7 and angiopoietin [8] [9] [10] [11] families, regulate angiogenesis through multiple and overlapping molecular pathways in various physiological and pathological processes. 12 Although each of these growth factors has been described to play a dominantly pro-hemangiogenic (eg, VEGF-A 13 ) or pro-lymphangiogenic (eg, VEGF-C and VEGF-D 13 ) function, their in vivo effect is more complex because the function of these factors is affected by the microenviroment in which they are expressed.
Investigation of the distinctive molecular and cellular mechanisms underlying the growth of corneal blood, as opposed to lymphatic, vessels has been particularly challenging because the majority of the pathological conditions and animal models stimulate coincident growth of both lymphatic and blood vessels. 14 Multiple groups have defined strategies to selectively induce blood or lymphatic growth in the cornea. One example is basic FGF (b-FGF), which was initially characterized as an inducer of hemangiogenesis, whereas intrastromal micropellet implantation of very low doses of b-FGF (12.5 ng) was subsequently shown to be a selective lymphangiogenic stimulator. In addition, we and others have shown that systemic blockade of VEGFR3 15, 16 and a5 integrin 17 predominantly inhibits corneal lymphangiogenesis.
Very little is known about the relative contribution of blood versus lymphatic vessels to various pathological conditions of the cornea. This is relevant because pathological angiogenesis of the cornea, as appreciated in clinical cases, is highly heterogeneous, not just from eye to eye, but also within the same cornea. Here we study the spatial variances in ligand expression and angiogenic effects in response to the same inflammatory stimulus induced by b-FGF.
MATERIALS AND METHODS

Animals
Male 6-to 8-week-old Balb/c mice were used in all experiments. Animals were anesthetized by intraperitoneal injection of ketamine (120 mg/kg) and xylazine (20 mg/kg) before any surgery and were treated in accordance with ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Experiments described herein were conducted under institutional animal care and use committee approval.
Pellet Implantation b-FGF micropellets (80 ng/pellet) were prepared as described previously. 18 To implant the pellets, half thickness linear incisions were made at the center of cornea using a disposable 30-degree microknife (Fine Science Tools, Foster City, CA). Lamellar pocket incisions were then made parallel to the corneal plane using a Von Graefe knife (Fine Science Tools) and advanced to the temporal limbus at the lateral canthal area. The pellets were positioned into the pocket 1.0 mm apart from the limbal vascular arcade on the temporal side, and tetracycline ophthalmic ointment was applied to the eye after pellet implantation.
Immunohistochemistry and Morphometry of Lymphangiogenesis and Hemangiogenesis
After taking photographs under the slit lamp, 5 mice per group were killed 1, 3, and 7 days after implantation. Freshly enucleated eyes were prepared into corneal flat mounts. Immunohistochemical staining was performed with FITC-conjugated CD31/PECAM-1 (rat antimouse antibody; 1:100; Santa Cruz Biotechnology, Santa Cruz, CA). Staining against LYVE-1 (lymphatic endothelium-specific hyaluronic acid receptor; goat antirabbit antibody; 1:400; Abcam, Cambridge, MA) was also performed with purified antibody followed by rhodamine-conjugated secondary antibody. To quantify the level of blood vessel (CD31 high /LYVE-1 low ) or lymphatic vessel (CD31 low /LYVE-1 high ) formation, low magnification (·2) micrographs were captured, and the area covered by each type of vessels was calculated (NIH ImageJ software 1.34; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html) and expressed as the percentage of total corneal area (%).
Quantitative Real-Time Polymerase Chain Reaction
Corneas were harvested on days 1, 3, and 7 postimplantation. In a group of animals, each cornea was divided into 2 different areas based on the proximity to the pellet: prepellet area (PA) or temporal cornea, and the opposite-pellet area (OA) or the nasal part of the cornea. RNA was isolated from either the whole or different regions of the cornea by RNeasy Micro Kit (Qiagen, Valencia, CA) and reverse transcribed (Superscript III Kit; Invitrogen Life Technologies, Carlsbad, CA). Real-time polymerase chain reaction (RT-PCR) was performed (TaqMan Universal PCR MasterMix; Applied Biosystems, Foster City, CA), and primers were preformulated for VEGF-A (assay ID Mm00437304_ml), VEGF-C (assay ID Mm00437313_ml), and VEGF-D (assay ID Mm00438965_ml), (Applied Biosystems). PCR conditions were 2 minutes at 50°C, 10 minutes at 95°C, followed by 35 cycles of 15 seconds at 95°C and 60°C for 1 minute using an ABI PRISM 7900 HT (Applied Biosystems). The results were analyzed by the comparative threshold cycle method. The relative expression level of each sample was expressed compared with 10 5 of GAPDH using Microsoft Office Excel 2003.
Statistical Analysis
Error bars displayed in the figures were calculated from the standard error of the mean (±SEM). Statistical analysis of blood and lymphatic vessel area was performed using a oneway analysis of variance. Student's t test was performed to compare the level of messenger RNA in quantitative RT-PCR. P , 0.05 was considered statistically significant.
RESULTS
b-FGF Induces Corneal Angiogenesis and Upregulates VEGF Ligand Expression
Hemangiogenic properties of b-FGF have long been studied. However, its recently identified pro-lymphangiogenic properties have not been well characterized. Using immunostaining for specific markers of blood and lymphatic vessel, we showed that implantation of b-FGF micropellets results in extensive corneal hemangiogenesis and lymphangiogenesis ( Fig. 1B) . As the pro-angiogenic effects of b-FGF are believed to be mediated through VEGF, 19 we examined the expression levels of VEGF ligands at different time points after corneal implantation of the b-FGF micropellets. As shown in Figure  1C , corneal messenger RNA expression of all 3 principal VEGF ligands, VEGF-A, VEGF-C, and VEGF-D, were significantly upregulated after b-FGF micropellet implantation compared with normal levels, implicating these VEGF species in b-FGF induced corneal neovascularization.
b-FGF Promotes a Spatially Distinct Pattern of Lymphangiogenesis and Hemangiogenesis
As illustrated in Figure 2 , we observed a robust hemangiogenic response in the limbal-peripheral cornea closest to the pellet (PA), whereas lymphatics grew more primarily in the limbal-peripheral cornea opposite to the pellet (OA) toward the center. This distinct spatial pattern of blood and lymphatic growth was consistently observed at different time points after implantation of b-FGF micropellets. Quantification of the relative area of the corneas covered by each vessel type (Fig. 3) showed that on the PA of the corneas 92% are blood vessels and only 8% are lymphatic vessels. In contrast, on the OA, there was nearly 3 times as much of the cornea covered by lymphatics (77%) compared with blood vessels (23%).
b-FGF Induces VEGF Ligands in a Spatially Distinct Pattern
Further, to evaluate the relative expression of VEGF ligands in different areas of cornea by b-FGF micropellet, we used quantitative real-time PCR of VEGF ligands in PA and OA. Consistent with our in situ results on lymphatic and blood vessel growth induced by b-FGF micropellet, we observed that VEGF ligands were upregulated in a spatially distinct manner in the cornea (Figs. 4A-C). VEGF-A and VEGF-C ligands were mainly upregulated in the PA, whereas in the OA there were significant increases in VEGF-D and VEGF-C, and to a lesser extent in VEGF-A compared with the normal state. This pattern of VEGF ligand upregulation was consistent with the "phenotype" observed in the corneal immunofluorescent staining for lymphatic and blood vessel growth.
DISCUSSION
Angiogenesis is an intricate process that involves many cell types through a diverse group of growth factors and signaling pathways. FGF is a potent angiogenic factor, [19] [20] [21] [22] which contributes to the pathogenesis of corneal inflammatory diseases through interactions with other angiogenic factors, including VEGF. Here we evaluated the pattern of angiogenesis induced by FGF micropellet and demonstrate that it results in a spatially distinct modulation of VEGF ligand expression and resultant growth of lymphatic versus blood vessels in the cornea.
Accumulating evidence is challenging the original characterization of angiogenic phenotypes through receptorligand-specific interactions. Angiogenesis is not interrupted in the double knockout of FGF1 and FGF2, indicating extensive redundancy of the ligand system. [23] [24] [25] On the other hand, although exogenous FGF2 is able to induce vascular structure formation in normal embryos, VEGF-R2−/− embryos fail to develop vessels in the presence of b-FGF. 26 These findings support the idea that FGF may act upstream to VEGFs. Supporting this concept is our finding that all VEGF ligands are overexpressed in the presence of b-FGF stimulation in the cornea.
The novel finding in this study is the observed high lymphangiogenic response noted after b-FGF stimulation in the cornea on the opposite side of where the FGF pellet is implanted. More importantly, we observed differential patterns of VEGF stimulation by b-FGF micropellet in various parts of the cornea, with high levels of VEGF-D expression on the OA.
Our findings have several interesting implications for our assessment of immunity in the setting of corneal inflammatory angiogenesis. First, given that the majority of cases of corneal angiogenesis are sectoral rather than diffuse, it is provocative to hypothesize that ample lymphatics may well be present in areas of the cornea directly opposite to the clinically visible blood vessels and adjacent area of stromal inflammation. Given that corneal lymphatics, which cannot be seen directly by slit lamp examination, play a crucial role in the induction and amplification of alloreactive 27 and autoimmune 28 responses to corneal antigens, these findings suggest that continued induction of immune reactivity could be ongoing, away from the site of inflammation even in a setting where the therapy has led to blood vessel regression. Put another way, inflammatory changes that induce even sectoral corneal angiogenesis likely lead to more "global" changes in corneal immunity. This concept is indirectly supported by the definition of risk factors for rejecting a corneal graft, which induces as little as 1 to 2 quadrants of neovascularization in the host bed. 29 Additionally, given the development of in vivo imaging technologies that allow for imaging and monitoring of corneal lymphatics, 30 our data imply that the area likely requiring our focus for assessment of lymphatics also includes the area opposite to the site of inflammation.
Here, we show for the first time that both processes of blood and lymphatic growth can potentially happen at the same time but in different locations in the cornea in response to differential expression of VEGF ligands, suggesting more global changes in corneal immunity and predilection for inflammation beyond that which is directly visible by slit lamp examination. 
